l e t t e r s
Humans are colonized by a large and diverse bacterial flora (the microbiota) essential for the development of the gut immune system [1] [2] [3] . A broader role for the microbiota as a major modulator of systemic immunity has been proposed 4,5 ; however, evidence and a mechanism for this role have remained elusive. We show that the microbiota are a source of peptidoglycan that systemically primes the innate immune system, enhancing killing by bone marrow-derived neutrophils of two major pathogens: Streptococcus pneumoniae and Staphylococcus aureus. This requires signaling via the pattern recognition receptor nucleotide-binding, oligomerization domain-containing protein-1 ( Nod1, which recognizes meso-diaminopimelic acid (mesoDAP)-containing peptidoglycan found predominantly in Gram-negative bacteria), but not Nod2 (which detects peptidoglycan found in Gram-positive and Gram-negative bacteria) or Toll-like receptor 4 ( Tlr4, which recognizes lipopolysaccharide) 6, 7 . We show translocation of peptidoglycan from the gut to neutrophils in the bone marrow and show that peptidoglycan concentrations in sera correlate with neutrophil function. In vivo administration of Nod1 ligands is sufficient to restore neutrophil function after microbiota depletion. Nod1 −/− mice are more susceptible than wild-type mice to early pneumococcal sepsis, demonstrating a role for Nod1 in priming innate defenses facilitating a rapid response to infection. These data establish a mechanism for systemic immunomodulation by the microbiota and highlight potential adverse consequences of microbiota disruption by broadspectrum antibiotics on innate immune defense to infection.
Humans are colonized by approximately 1 × 10 13 to 1 × 10 14 bacteria that reside primarily on the mucosal surfaces of the host 8 . Understanding host-bacteria relationships has generally focused on pathogenesis; however, bacterial infections are relatively rare, and the predominant host-bacteria interactions are usually benign and often beneficial. The local effects of the microbiota on gut homeostasis 9 and gut immune development 10, 11 have been delineated; however, few studies have addressed the systemic effect of the microbiota 12 . A broader influence of the microbiota in the regulation of systemic immunity, resulting from the translocation of microbial products from the luminal side of the mucosa into the circulation, has been proposed 4, 13 . However, evidence to support such an effect remains preliminary, and an understanding of the mechanisms involved is lacking.
Neutrophils are a crucial component of the innate immune system and are often the initial defense against extracellular pathogens 14 . We have previously shown that local recognition of peptidoglycan by the pattern recognition receptor Nod1 enhances killing of complementopsonized S. pneumoniae by neutrophils 15 (Fig. 1a) . To ascertain whether this is a general mechanism of neutrophil activation, we investigated opsonophagocytic killing of another major pathogen, S. aureus, which, in contrast to S. pneumoniae, requires the oxidative burst for effective killing 16 . Neutrophils from the peritoneal cavity of mice administered (intraperitoneally (i.p.)) heat-killed Haemophilus influenzae, a Gram-negative bacterium with mesoDAP-containing peptidoglycan, showed enhanced killing of S. aureus in an ex vivo opsonophagocytic assay compared to neutrophils from unstimulated control mice (Fig. 1b) . However, neutrophils from Nod1 −/− mice were refractory to stimulation with heat-killed H. influenzae, confirming that local recognition of peptidoglycan by Nod1 enhances opsonophagocytic killing of both S. pneumoniae and S. aureus. This indicates that Nod1 has a broad influence on neutrophil function, activating both oxidative and nonoxidative mechanisms of killing.
Notably, we observed that neutrophils from Nod1 −/− mice not only were unresponsive to stimulation by exogenous peptidoglycan but also showed defects in their basal level of killing in the absence of additional stimulation (in a comparison of S. pneumoniae and S. aureus killing by neutrophils from unstimulated control wild-type and Nod1 −/− mice) (Fig. 1a,b) . We hypothesized that recognition of microbial products under basal conditions (in the absence of infection) systemically primes the innate immune system, enhancing neutrophil function, and that the host microbiota provide this stimulus. To investigate this hypothesis, we gave mice broad-spectrum antibiotics and assessed the systemic effect of microbiota depletion on bone marrow-derived neutrophil function. We confirmed by flow cytometry that, analogous to neutrophil-enriched peritoneal exudate cells (PECs), the cell population enriched from the bone marrow interacting with bacteria was Ly6G + cells (that is, neutrophils), and this interaction was dependent on the opsonization of bacteria by complement (data not shown). Neutrophils isolated from the bone l e t t e r s marrow of antibiotic-treated mice and tested in an ex vivo opsonophagocytic assay showed a significant reduction in killing of S. pneumoniae and S. aureus compared to those from control mice not treated with antibiotics ( Fig. 1c,d ). Bone marrow-derived neutrophils from mice maintained in a germ-free environment also showed reduced killing of S. pneumoniae and S. aureus compared to those from previously germ-free mice that were removed from germ-free conditions (conventionalized), confirming the systemic role of the microbiota in enhancing neutrophil function (Fig. 1e,f) .
To define the mechanism by which the microbiota exert this effect, we treated mice deficient in the pattern recognition receptors for various microbial products (Nod1 −/− , Nod2 −/− and Tlr4 −/− mice) with broad-spectrum antibiotics. Bone marrow-derived neutrophils from antibiotic-treated Tlr4 −/− and Nod2 −/− mice showed a significant reduction in the killing of both S. pneumoniae and S. aureus compared to untreated mice, showing that neither lipopolysaccharide nor N-acetylmuramyl-l-alanyl-γ-d-glutamate (MDP) from the microbiota are necessary for systemic innate immune activation in this model (Fig. 1g,h ). In contrast, bone marrow-derived neutrophils from Nod1 −/− mice were not only defective in killing S. pneumoniae and S. aureus but also unresponsive to signals from the microbiota, showing that recognition of peptidoglycan from the microbiota by Nod1 is crucial for maintaining a basal level of immune activation. Next, we addressed how the microbiota communicate systemically to sites distal to the gut and whether peptidoglycan from the gut microbiota is translocated from the luminal side of the mucosa into the host circulation under basal conditions (in the absence of infection). The translocation of microbial products has been documented previously; however, the effects of these products have generally been considered in the context of compromised barrier function due to viral or bacterial infection 17, 18 . In addition, specific mechanisms for the uptake of peptidoglycan fragments from the colonized mucosa have been proposed 19, 20 . We stably colonized the guts of mice, as they were removed from germ-free conditions, with Escherichia coli with [ 3 H]DAP-labeled peptidoglycan for 3 d (Fig. 2a) . We detected systemic peptidoglycan in sera, and the concentrations correlated with those in feces (Fig. 2a,b) . This indicates that, during colonization, peptidoglycan is constantly turned over and either excreted or translocated across the gut mucosa into the circulation. Furthermore, during colonization peptidoglycan accumulated in the bone marrow (Fig. 2b) and could be detected in the neutrophil fraction (72 h after oral inoculation, 0.043% ± 0.014% of total c.p.m. of inoculum per 1 × 10 9 neutrophils). To demonstrate that the translocated peptidoglycan was active, we added sera from either antibiotic-treated, untreated, germ-free or previously germ-free conventionalized mice to a bioassay using HEK293T human embryonic kidney cells carrying a nuclear factor-κB (NF-κB)-luciferase reporter and transfected with either a Nod1 or a Nod2 construct. In this bioassay, addition of mouse sera elicited both Nod1-and Nod2-dependent NF-κB activation, confirming the presence of translocated peptidoglycan (Fig. 2c,d) . Sera from germ-free and antibiotic-treated mice elicited significantly less Nod1-and Nod2-dependent NF-κB activation than sera from previously germ-free conventionalized and untreated mice, respectively (Fig. 2c,d) . These results indicate that the decrease in Nod1-dependent neutrophil killing correlates with decreased systemic concentrations of Nod1-activating peptidoglycan fragments.
To determine whether Nod1 ligands alone are sufficient to restore innate immunity after microbiota depletion, we treated mice with broad-spectrum antibiotics and then administered (i.p.) N-acetylmuramyl-l-alanyl-γ-d-glutamyl-meso-2,6-diaminopimelic acid (MurNAcTri DAP ) (the Nod1 ligand), MDP or vehicle controls. Bone marrow-derived neutrophils from mice treated with MurNAcTri DAP , but not MDP, showed more killing of S. pneumoniae, compared to mice treated with vehicle control, confirming that fragments of peptidoglycan found systemically, recognized by Nod1, are sufficient to activate neutrophils after microbiota depletion (Fig. 3a) . Additionally, we confirmed the expression of Nod1 
l e t t e r s in bone marrow-derived neutrophils by RT-PCR (data not shown).
We have previously shown that neutrophils are required to control sepsis from pneumococcal infection of the upper respiratory tract 21 . To investigate the role of Nod1 in priming innate immunity, we challenged wild-type (WT) C57BL/6 and Nod1 −/− mice intranasally with S. pneumoniae. Nod1 −/− mice were more susceptible to early sepsis (day 3, P = 0.0176; day 4, P = 0.0437) than WT mice; however, there was no difference in overall survival (after day 5) between Nod1 −/− and WT mice (Fig. 3b) . This suggests that Nod1 −/− mice have delayed responses to infection resulting from a lack of innate immune priming rather than any intrinsic defects. We then determined whether neutrophils can be directly activated by peptidoglycan. We treated HL-60 human promyelocytic cells that had previously been differentiated to a neutrophil-like phenotype with MurNAcTri DAP , MDP or vehicle controls. Treatment with MurNAcTri DAP , but not MDP, increased killing of S. pneumoniae by the cells compared to treatment with vehicle control (Fig. 3c) , indicating that peptidoglycan recognized by Nod1, but not Nod2, can directly enhance neutrophil function. This enhancement by MurNAcTri DAP treatment required the ability of Nod1 to activate the transcription factor NF-κB (Fig. 3c) . Neutrophils isolated from human whole blood also showed significantly more killing of S. pneumoniae after treatment with MurNAcTri DAP (Fig. 3d) . Previous work [22] [23] [24] and the data presented here have shown that microbial products derived from the microbiota are found systemically; however, there is little appreciation of how they affect the host. Depletion of the microbiota markedly lowered systemic peptidoglycan concentrations, which correlated with less killing of S. pneumoniae and S. aureus by bone marrow-derived neutrophils. We show that the peptidoglycan recognized by Nod1 is sufficient to restore neutrophil function in the absence of the microbiota, and, in the absence of Nod1 signaling, there is a failure to prime the innate immune system both in vitro in our cell culture model and in vivo. 
l e t t e r s
Our data reveal a previously undescribed role for peptidoglycan in priming systemic innate immunity and for Nod1 as a homeostatic regulator. Our data challenge the traditional view of innate immunity as quiescent in the absence of infection and activated only upon pathogen recognition 25 . We propose that the microbiota constantly modulate the innate immune system, priming it, thus facilitating a rapid response to pathogens such as S. pneumoniae and S. aureus that might otherwise quickly overwhelm innate defenses. This systemic effect of microbial products means that disruption of the microbiota, with a concomitant lowering of systemic immune activation, may have profound consequences on the host, rendering it more susceptible to infections. This may be a factor in the prevalence of secondary infections that occur after broad-spectrum antibiotic therapy 26 . There is increasing discussion regarding the beneficial, or 'probiotic', role of the microbiota; however, the mechanism by which the microbiota exert these effects are vague and inferred. Our data provide a direct example and mechanism for a probiotic activity of the microbiota, demonstrating that translocated microbial products found systemically benefit the host by enhancing systemic innate immune function.
MeTHoDs
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
